Lilly buys ARMO for $1.6 billion
Eli Lilly will buy ARMO BioSciences for $50 per share, or approximately $1.6 billion, the companies said Thursday.
Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly will buy ARMO BioSciences for $50 per share, or approximately $1.6 billion, the companies said Thursday.
AstraZeneca and Merck have gotten EMA’s approval of Lynparza tablets for use twice daily, as a maintenance therapy for patients…
Euronext listed biopharma company Probiodrug AG, a clinical stage developer therapeutics to treat Alzheimer’s disease (AD), has announced that results…
Alcon, a division of Novartis, will give 100 reprocessed Infiniti units to eligible clinics in Asia, Central and South America,…
LEH Pharma, the provider of novel ocular implants for macular disorders, has appointed Sir Henry Riley as Chairman of the…
Hikma Pharmaceuticals’s US subsidiary West-Ward Pharmaceuticals has launched Methotrexate for Injection, USP in a 1g preservative-free presentation and Methotrexate Injection,…
Concepta has signed an agreement with SinoPharm, the largest state-owned pharmaceutical company in China, with annual sales of over £23…
Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow…
AstraZeneca and MedImmune, its global biologics research and development arm, brought to public high-level results from the Phase III ARCTIC…
Sanofi’s Head of Global Research and Development, Elias Zerhouni, will retire from the company after more than 9 years, in the…